Bormioli Pharma grows sales by more than 40 percent
Bormioli Pharma has announced growth in its North American business in 2022, with sales increasing more than 40% year-over-year.
The growth in North America was matched by sales gains in the company’s markets worldwide, reflecting Bormioli’s investments in expanding its capabilities as a provider of packaging solutions for injectable drugs.
The US glass bottle market is dealing with continuing supply issues for injectable glass packaging as a result of lingering effects of the COVID-19 pandemic and resulting supply chain disruptions. Bormioli claims to provide a solution with its expanding capabilities in the area of glass vials, rubber stoppers and aluminium seals. Specifically, the company has invested in strengthening its tubular glass vials capabilities through advanced machinery, while upgrading its platform for moulded glass, and expanding cleanroom capabilities for the production of rubber stoppers.
“For almost 200 years, we have been leading the field of moulded glass manufacturing and now we have expanded those capabilities to tubular glass vials designed for injectable drugs and vaccines,” noted Bormioli pharma chief executive officer Andrea Lodetti. “Our proud history is matched by our current passion for innovation in the provision of innovative comprehensive packaging solutions for drug makers. As a single supplier of all the components of the injection drug kit, we can offer a wide variety of cost-effective, flexible solutions tailored to the customer’s needs, while also pursuing an ambitious agenda to greatly increase the sustainability of all our operations. Our multi-faceted commitments are driven by two major factors – the supply chain issues from the continuing shortage of glass packaging for injectable drugs and the stark reminders of the inescapable dangers of ongoing climate change.”
Bormioli Pharma’s products aim to ensure maximum drug stability by protecting drugs from deterioration, prolonging medication stability, and providing accurate dosing, thereby contributing to the health of individuals receiving treatment.
In anticipation of its upcoming 200th anniversary, Bormioli Pharma launched “50-in-5,” a programme to achieve 50% of sustainable raw materials in its pharmaceutical packaging production by 2025. “50-in-5” is a project impacting the entire manufacturing footprint. To achieve this goal, the company has been expanding its industrial platform, with investments of more than 50 million euros to date that will be matched by similar investments over the next three years. Strategies include increasing the percentage of recycled materials throughout the production process and adopting carbon capture and other green materials for container closure components and seals.